• AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)

    来源: Nasdaq GlobeNewswire / 03 1月 2022 09:10:59   America/Los_Angeles

    N/A
分享